Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone hexacetonide
Drug ID BADD_D02274
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Prescription
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00985
MeSH ID C005900
PubChem ID 21826
TTD Drug ID Not Available
NDC Product Code 52128-177; 46439-8728; 59137-570
Synonyms triamcinolone hexacetonide | 9-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-(3,3-dimethylbutyrate) | Aristospan
Chemical Information
Molecular Formula C30H41FO7
CAS Registry Number 5611-51-8
SMILES CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)COC(=O)CC(C)(C)C)C)O)F)C)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abscess sterile08.01.05.008--Not Available
Acne23.02.01.001--Not Available
Alkalosis hypokalaemic14.01.02.002--Not Available
Alopecia23.02.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Arachnoiditis12.02.04.002; 17.06.01.001--
Arrhythmia02.03.02.001--Not Available
Blindness06.02.02.001; 17.17.01.003--Not Available
Blood potassium decreased13.11.01.010--Not Available
Bradycardia02.03.02.002--Not Available
Calcinosis08.03.04.002--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure congestive02.05.01.002--Not Available
Cardiomegaly02.04.02.001--Not Available
Cataract subcapsular06.06.01.002--Not Available
Circulatory collapse24.06.02.001--Not Available
Cushingoid05.01.01.002; 14.11.01.006; 19.07.03.001; 24.08.02.004--
Depression19.15.01.001--
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Dry skin23.03.03.001--
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Erythema23.03.06.001--Not Available
Euphoric mood19.04.02.006--
Exophthalmos05.02.02.002; 06.09.04.001--Not Available
Fat embolism12.01.08.003; 24.01.01.012--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages